Product List     API & Intermediate     

Antineoplastic Agents

Find
134
related chemicals for you
CAS:147-94-4
Molecular Formula:C9H13N3O5
Cytosine β-D-Arabinofuranoside; 4-Amino-1-((2R,3S,4S,5R)-3,4-Dihydroxy-5-(Hydroxymethyl)Tetrahydrofuran-2-Yl)Pyrimidin-2(1H)-One; 4-Amino-1-β-D-Arabinofuranosyl-2(1H)-Pyrimidinone; 4-Amino-1-[(2R,3S,4S,5R)-3,4-Dihydroxy-5-(Hydroxymethyl)Oxolan-2-Yl]Pyrimidin-2-One; Cytosine β-D-Arabinofuranosid; Depocyt (Cytarabine); 4-Amino-1-[(2R,3S,4S,5R)-3,4-Dihydroxy-5-(Hydroxymethyl)Oxolan-2-Yl]-1,2-Dihydropyrimidin-2-One; 4-Amino-1-Beta-D-Arabinofuranosyl-2(1H)-Pyrimidinone; Arabinocytidine; Cytosine Beta-D-Arabinofuranoside; Ara-C; Ara-Cell
Brief Introduction
Cytarabine is a kind of purine nucleoside antiviral drug which is extracted from Streptomyces culture medium and synthesized by chemical method. It is slightly soluble in water, and its monophosphate is easily soluble in water. It can inhibit HSV1 and HSV2, hepatitis B virus, varicella zoster virus and cytomegalovirus, but has no effect on smallpox virus, adenovirus, other DNA or RNA viruses, bacteria and fungi. At present, the exact mechanism of cytosine arabinoside antiviral has not been fully elucidated, which is mainly related to the inhibition of virus replication. Drugs and their metabolites block the synthesis of viral DNA by inhibiting viral DNA polymerase, while drugs only penetrate into viral DNA molecules in a very small amount. Cytarabine is also one of the most effective drugs for the treatment of acute non lymphocytic myeloid leukemia in China.
CAS:154229-19-3
Molecular Formula:C24H31NO
(3Beta)-17-(3-Pyridinyl)-Androsta-5,16-Dien-3-Ol; Androsta-5,16-Dien-3-Ol, 17-(3-Pyridinyl)-, (3Beta)-; Cb 7598; Cb-7598; Unii-G819A456D0; Abiraterone(Cb-7598); 17-(3-Pyridyl)Androsta-5,16-Dien-3Beta-Ol; Cb7598; Zytiga
Brief Introduction
Abiraterone acetate (INN, USAN, BAN, JAN) (brand names Zytiga, Abiratas, Abretone, Abirapro) is a steroidal antiandrogen, specifically an androgen synthesis inhibitor, used in combination with prednisone in metastatic castration-resistant prostate cancer (previously called hormone-resistant or hormone-refractory prostate cancer) – i.e., prostate cancer not responding to androgen deprivation or treatment with androgen receptor antagonists. It is a prodrug to the active agent abiraterone, and is marketed by Janssen Biotech under the trade name Zytiga. In addition, Intas Pharmaceuticals markets the drug under the trade name Abiratas, Cadila Pharmaceuticals markets the drug as Abretone, and Glenmark Pharmaceuticals as Abirapro. Abiraterone acetate was approved by the United States Food and Drug Administration on April 28, 2011. The FDA press release made reference to a phase III clinical trial in which abiraterone use was associated with a median survival of 14.8 months versus 10.9 months with placebo; the study was stopped early because of the successful outcome.
CAS:154361-50-9
Molecular Formula:C15H22FN3O6
Pentyl [1-(3,4-Dihydroxy-5-Methyl-Oxolan-2-Yl)-5-Fluoro-2-Oxo-Pyrimidin-4-Yl]Aminoformate; Xeloda; Capecytabine; Ro 09-1978; Captabin; 5'-Deoxy-5-Fluoro-N-[(Pentyloxy)Carbonyl]Cytidine; Ro-9-1978; 5'-Deoxy-5-Fluoro-N4-[(Pentyloxy)Carbonyl]Cytidine; Cpecitabine; Capecitibine; Ro 09-1978/000; Capcitabine; 5'-Deoxy-5-Fluorocytisine; Pentyl (1-((2R,3R,4S,5R)-3,4-Dihydroxy-5-Methyltetrahydrofuran-2-Yl)-5-Fluoro-2-Oxo-1,2-Dihydr
Brief Introduction
Capecitabine, an antimetabolite fluoropyrimidine deoxynucleoside carbamate that can be converted to 5-FU in vivo, was developed by Roche under the trade name hiloda and is able to inhibit cell division and interfere with RNA and protein synthesis. For further treatment of paclitaxel and advanced primary or metastatic breast cancer including patients refractory to chemotherapeutic regimens with anthracyclines. It is mainly used for the treatment of advanced primary or metastatic breast, rectal, colon and gastric cancer.
Mixed Tocopherols
Brief Introduction
Using mixed tocopherol concentrate as raw material, various specifications of mixed natural vitamin E are purified and compounded through chemical processes such as pretreatment, adsorption separation and molecular distillation.
CAS:641571-10-0
Molecular Formula:C28H22F3N7O
Tasigna; Nilotinib (Amn-107); Its Intermediates; Nilotinib For Research; Nilotinib(Amn 107); Nilotinib,Amn107,Tasigna; Amn 107; Nilotinib D6
Brief Introduction
Nilotinib is a new targeted tumor therapeutic drug, which belongs to tyrosine kinase inhibitor. It is used to treat patients with chronic myeloid leukemia (CML) resistant to glipizide (imatinib). Gleevec is the preferred drug developed by Novartis for the treatment of chronic myeloid leukemia (CML). Nilotinib is improved from the molecular structure of imatinib. It has stronger selectivity for bcr-abl kinase activity. Its inhibitory effect on tyrosine kinase is 30 times stronger than imatinib. It can inhibit the kinase activity of BCR-ABL mutant resistant to imatinib. It can also inhibit kit and PDGFR kinase activities.
Inquiry ( 
10
 
/ 10
 )
Clear All
Sign In
Please enter your email address correctly
Please enter your password
Forgot Password
OR
Join Free >